Alagille Syndrome Treatment MarketSize and Trends
The global alagille syndrome treatment market is estimated to be valued at US$ 88.9 Million in 2023 and is expected to exhibit a CAGR of 6.6% during the forecast period (2023-2030).
Figure 1. Global Alagille Syndrome Treatment Market Share (%), By Drug, 2023
Global Alagille Syndrome Treatment Market - Drivers
- Increasing interest by researchers and key market palyers : There is an increase in interest among researchers and key market players to explore Alagille syndrome treatment options more effectively. This is primarily due to its potential to significantly improve the quality of life of patients and address unmet medical needs in this rare genetic disorder. Alagille syndrome is a complex condition that affects multiple organ systems including the liver, heart, and kidneys. As current treatment options are limited and often focused on managing symptoms, there is a growing urgency to develop innovative therapies that can target the underlying cause of the syndrome. By advancing research in this area, researchers and market players aim to provide hope for patients and their families by offering more effective and tailored treatment approaches. These therapies could potentially improve the quality of life for individuals with Alagille syndrome and reduce the need for invasive procedures such as liver transplants. Additionally, by understanding the underlying cause of the syndrome, researchers may be able to identify potential biomarkers or genetic targets that could lead to earlier diagnosis and intervention.
Global Alagille Syndrome Treatment Market Segmentation:
The global alagille syndrome treatment market report is segmented into drug, distribution channel, and region.
- By drug, the market is segmented into ursodeoxycholic acid, cholestyramine, rifampicin, late stage pipeline drugs, and others. Out of which, ursodeoxycholic acid is expected to hold a dominant position in the global alagille syndrome treatment market during the forecast period, and this is attributed to the increasing ursodeoxycholic acid use for the development of new drugs to treat alagille syndrome.
- By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, hospital pharmacies is expected to dominate the market over the forecast period, and this is attributed to the increasing patient pool of Alagille syndrome.
- Among all the segmentation, the drug segment is expected to dominate the market over the forecast period, and this is explained by the rising preference of pharmaceutical raw materials for the creation of new medications to treat Alagille syndrome.
Global Alagille Syndrome Treatment Market: Key Trends
- Approval and launch of new drugs for the treatment: The launch of drug in more than one region for the treatment of Alagille syndrome is expected to drive the growth of the global alagille syndrome treatment market over the forecast period. For instance, in December 2022, Mirum Pharmaceuticals, Inc., a biopharmaceutical company, announced that the European Commission has granted marketing authorization for LIVMARLI (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) two months of age and older. The approval follows a positive opinion granted by the European Committee for Medicinal Products for Human Use (CHMP) in September 2022. LIVMARLI is the first and only approved treatment in both the European Union and the U.S. to treat this rare liver disease affecting one out of 30,000 people globally.